Bruni D, K Angell H and Galon J

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Nature Reviews Cancer

doi: 10.1038/s41568-020-0285-7

O’Connor JM, Esteso F & Chacón M

Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine

Future Medicine

Colorectal Cancer | Ahead of Print

Blair H

Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer

Molecular Diagnosis & Therapy volume

24, pages365–370(2020)

Marliot F, Chen X, Kirilovsky A et al.

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer


Sinicrope F, Shi Q, Hermitte F et al.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

JNCI Cancer Spectrum

Volume 4, Issue 3, June 2020, pkaa023

Pages F, Andre T, Taieb J et al.

Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study

Annals of Oncology

PMID: 32294529

Pages F, Andre T, Taieb J et al.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of Clinical Oncology

Volume 37, Issue 15_suppl

Galon J & Bruni D

Tumor Immunology and Tumor Evolution: Intertwined Histories


Galon J & Bruni D

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Nat Rev Drug Discov.


Mlecnik B, Bindea G, Angell HK et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.



Galon J, Costes A, Sanchez-Cabo F et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.



Pagès F, Kirilovsky A, Mlecnik B et al.

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

J Clin Oncol.


Mlecnik B, Tosolini M, Kirilovsky A et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

J Clin Oncol.


Kirilovsky A, Marliot F, El Sissy C et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Int Immunol.


Pagès F, Mlecnik B, Marliot F et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.


391 (10135)

Sinicrope F, Shi Q, Hermitte F et al.

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

J Clin Oncol.

35:15s (suppl; abstr 3579)

Sinicrope F, Shi Q, Hermitte F et al.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

J Clin Oncol.

36:4s (suppl; abstr 614)

Angelova M, Mlecnik B, Vasaturo A et al.

Evolution of Metastases in Space and Time under Immune Selection.



Fridman WH, Pagès F, Sautès-Fridman C, Galon J.

The immune contexture in human tumours: impact on clinical outcome.

Nat Rev Cancer.


Galon J, Angell HK, Bedognetti D, Marincola FM

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.



Bindea G, Mlecnik B, Tosolini M et al.

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.



Berghoff AS, Fuchs E, Ricken G et al.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.



Mlecnik B, Bindea G, Kirilovsky A et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med.


Galon J, Mlecnik B, Marliot F et al.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

J Clin Oncol.


Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon.

Journal for ImmunoTherapy of Cancer


Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G

The immune contexture in cancer prognosis and treatment.

Nat Rev Clin Oncol.


Mlecnik B, Van den Eynde M, Bindea G et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst.


Angell HK, Bruni D, Barrett JC et al.

The Immunoscore: Colon Cancer and Beyond.

Clin Cancer Res.

doi: 10.1158/1078-0432

Zeitoun G, Sissy CE, Kirilovsky A et al.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Chirurgia (Bucur).


Mascaux C, Angelova M, Vasaturo A et al.

Immune evasion before tumour invasion in early lung squamous carcinogenesis.